tuvatexib IV (VDA-1102 IV) / Vidac Pharma - LARVOL DELTA

U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates (GlobeNewswire) - "Vidac Pharma Holdings Plc...today announces that the United States Patent and Trademark Office (USPTO) has issued a patent to the company offering broad protection of the mode of action underlying its oncology and onco-dermatologic therapeutic candidates. The patent protects the use of Vidac’s new chemical entities to detach the hexokinase2 isozyme from the mitochondrial VDAC pores to reverse the hyperglycolytic metabolism of cancer cells...Vidac Pharma’s two product candidates - VDA-1275 as well as the more advanced VDA-1102 - disrupt the interaction between hexokinase 2 (HK2) and the voltage-dependent anion channels (VDACs) in mitochondria."

Patent • Cutaneous T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates (GlobeNewswire) - "Vidac Pharma Holdings Plc...today announces it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) protecting a group of molecules and their ability to trigger an immune response across a wide range of cancers by detaching the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores. The molecules are the crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275."

Patent • Cutaneous T-cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor